Navigation Links
LSTM to lead $30 million research program into malaria in pregnancy

The Liverpool School of Tropical Medicine has received a $30 million grant from the Bill & Melinda Gates Foundation to improve the control and treatment of malaria in pregnancy in Africa, Asia and Latin America. The five year programme will directly benefit the 50 million women who face exposure to malaria whilst pregnant every year.

The grant will fund research at Liverpool and at 38 partner institutions in 27 countries around the world. The research consortium is also supported by the European Union, and is seeking additional funding from other donors.

Malaria in pregnancy is a major cause of severe maternal anaemia and preventable low birth weight in infants, which greatly increases risk of death. It is estimated that more effective control of malaria in pregnancy could save the lives of up to 100,000 children every year in Africa alone.

There is less detailed information on the effects of malaria in pregnancy outside Africa. Although transmission rates are lower, natural immunity is also lower, therefore the consequences of malaria infection are more often severe, with a much higher risk of the death of the mother, baby or both.

The primary aims of the research address four key areas:


  • Obtain a better understanding of the burden of malaria in pregnancy in regions outside Africa where malaria is common.


  • Further evaluate which of the new generation of antimalarial drugs can be used safely and effectively for the treatment of pregnant women with malaria in Africa, Asia and Latin America.


  • Identify safe alternative antimalarials for the prevention of malaria in pregnancy in Africa to replace the commonly used drug sulphadoxine-pyrimethamine (to which many malaria parasites have developed resistance).

  • Determine the most effective combinations of drugs and other tools that reduce the risk of mosquito bites (eg insecticide treated bednets), thus preventing malaria in pregnancy.

  • Evaluate new interventions for the control of malaria in pregnancy in low transmission regions outside of Africa.

Coverage and utilisation

  • Establish the best way to increase the coverage and utilisation of existing strategies to control malaria in pregnancy.

Consortium leader Dr Feiko ter Kuile explained: In contrast to the recent focus on preventing malaria deaths in young children, the impact of malaria in pregnancy has until now been a relatively neglected area of research. This grant provides researchers from all over the world with the opportunity to conduct a much expanded and much needed research programme that is focussed on this other high risk group.

There are four main research theme areas consisting of ten major projects. The work is conducted jointly by expert institutions from all over the world that have agreed to use standardized methods and share information. This consortium approach generates a new momentum of life-saving research, which will provide evidence-based policy changes in the shortest possible time.

Defeating malaria will require new and better tools to prevent and treat the disease in pregnancy, said Dr Regina Rabinovich, director of Infectious Diseases Development at the Gates Foundation. By undertaking this important research, Liverpool and its partners will help bring the world closer to the ultimate goal of malaria eradication.


Contact: Alan Hughes
Liverpool School of Tropical Medicine

Related medicine news :

1. Alleged Multi-Million Dollar Fraud Ring Target of Federal Lawsuit
2. Whole Planet Foundation(TM) (a Whole Foods Market Foundation) and Nobel Peace Prize Winner Dr. Muhammad Yunus Partner With Natural Foods Vendors, Pledging Over $1 Million to Help Combat Poverty
3. New Jersey Healthcare Consulting Firm to Pay U.S. $2.875 Million to Resolve Allegations of Medicare Fraud
4. Trevena, Inc. Announces $24 Million Series A Financing
5. Cathedral Healthcare System to Pay U.S. $5.3 Million to Resolve Allegations Involving Inflated Charges to Obtain Higher Medicare Reimbursement
6. LeMaitre Vascular Reports Q4 2007 Revenue of $11.1 Million, a 27% Increase
7. Robert H. Smith Feeding the Future with $15 Million Gift to Hebrew University of Jerusalem
8. Kidney Patient Advocacy Community Joins National Effort to Raise Awareness about Health Crisis Impacting more than 26 Million Americans
9. Cardinal Health Agrees to Acquire ChloraPrep(R) Manufacturer for $490 Million
10. NuVasive Prices $200 Million Convertible Senior Notes Due 2013
11. Cell Therapeutics, Inc. Announces Issuance of $51.7 Million of New 2012 Convertible Senior Notes
Post Your Comments:
(Date:11/26/2015)... CA (PRWEB) , ... November 26, 2015 , ... ... a new set of retro-fused, self-animating trailer titles with ProTrailer: Vintage. This newly ... options. These classically-influenced trailer titles work with any font, giving users limitless opportunities ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... the perfect dish and pleasing the palates of attendees is of the utmost ... dish to a seasonal get-together, give these recipes a try this holiday season. ...
(Date:11/25/2015)... ... November 26, 2015 , ... Ministers, senior government and ... Pan African Centres of Excellence, and public R&D institutions, civil societies and other ... of the 5th African Network for Drugs and Diagnostics Innovation, ANDI, Stakeholders Meeting. ...
(Date:11/25/2015)... ... November 25, 2015 , ... Dental professionals who would ... OH , are invited to attend Dr. Mark Iacobelli’s Advanced Implant Mentoring (AIM) CE ... Cleveland, OH. , As the co-founders of Advanced Implant Mentoring (AIM), Dr. Iacobelli ...
(Date:11/25/2015)... ... ... Smiles by Stevens is pleased to announce the addition of Botox® for the ... of the benefits of Botox® in the treatment of moderate facial wrinkling, few have ... pain as a result of Jaw Tension, TMJ (temporo-mandibular joint) disorder, and Bruxism (the ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... -- Allergan plc (NYSE: AGN ) today announced that ... York State Attorney General,s Office to end the ... statutes with the Attorney General over the decision of Forest ... selling the now generic version of memantine immediate release tablets.  ... released its counterclaims against New York , ...
(Date:11/25/2015)... -- Allergan plc (NYSE: AGN ), a ... start-up  biotechnology company focused on the development of ... by the F-Prime Biomedical Research Initiative (FBRI), today ... collaboration to support the discovery and development of ... Obsessive Compulsive disorders (OCD). ...
(Date:11/25/2015)... 2015 --> ... devices was valued at $11,171.1 million in 2014, and ... 5.7% during 2015 - 2022. The global market is ... of diabetes. In addition, the increase in obese population ... to the growth of the market. Furthermore, technological advancements ...
Breaking Medicine Technology: